Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

MLA

Anne F. Schott, et al. “Abstract GS3-03: GS3-03 ARV-471, a PROTAC® Estrogen Receptor (ER) Degrader in Advanced ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study.” Cancer Research, vol. 83, Mar. 2023, pp. GS3-03. EBSCOhost, https://doi.org/10.1158/1538-7445.sabcs22-gs3-03.

APA

Anne F. Schott, Sara Hurvitz, Cynthia Ma, Erika Hamilton, Rita Nanda, George Zahrah, Natasha Hunter, Antoinette R. Tan, Melinda Telli, Jesus Anampa Mesias, Rinath Jeselsohn, Pamela Munster, Haolan Lu, Richard Gedrich, Cecile Mather, Janaki Parameswaran, & Hyo S. Han. (2023). Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study. Cancer Research, 83, GS3-03. https://doi.org/10.1158/1538-7445.sabcs22-gs3-03

Chicago

Anne F. Schott, Sara Hurvitz, Cynthia Ma, Erika Hamilton, Rita Nanda, George Zahrah, Natasha Hunter, et al. 2023. “Abstract GS3-03: GS3-03 ARV-471, a PROTAC® Estrogen Receptor (ER) Degrader in Advanced ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study.” Cancer Research 83 (March): GS3-03. doi:10.1158/1538-7445.sabcs22-gs3-03.